Generex Biotechnology Corporation Executive Officer Base Salary Adjustment Notice (2005 & 2007)
Contract Categories:
Human Resources
›
Compensation Agreements
Summary
Generex Biotechnology Corporation's Board of Directors approved changes to the annual base salaries of its executive officers, effective retroactively to August 1, 2005, and January 1, 2007. The agreement lists the new salary amounts for Anna E. Gluskin (Chairman, President, and CEO), Rose C. Perri (COO, CFO, Treasurer, Secretary, and Director), and Mark Fletcher (Executive Vice President and General Counsel). This document formalizes the salary increases for these officers as of the specified dates.
EX-10.2 3 v086095_ex10-2.htm Unassociated Document
Exhibit 10.2
GENEREX BIOTECHNOLOGY CORPORATION
Annual Base Salaries for Executive Officers
Effective August 1, 2005 and January 1, 2007
On August 17, 2007, the Board of Directors of Generex Biotechnology Corporation implemented changes in annual base salary for its executive officers retroactive to effective dates of August 1, 2005 and of January 1, 2007 as follows:
| Annual Base Salary | ||
| Executive Officer | Increase Effective as of August 1, 2005 | Increase Effective as of January 1, 2007 |
| Anna E. Gluskin Chairman of the Board of Directors, President and Chief Executive Officer | $450,000 | $500,000 |
| Rose C. Perri Chief Operating Officer, Chief Financial Officer, Treasurer Secretary and Director | $350,000 | $400,000 |
| Mark Fletcher Executive Vice President and General Counsel | $275,000 | $300,000 |
